Dana-Farber Cancer Institute

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Dana-Farber Cancer Institute

https://www.dana-farber.org/

LYNKED IN Patient Conference 2024
Multiple Myeloma Patient Symposium
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)

By Dana-Farber Cancer Institute FEATURING Guru Sonpavde

0 views

June 24, 2019

Comments 0

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Genitourinary